Key result
High baseline plasma myeloperoxidase (≥1,150 ng/ml) was an independent predictor of 30-day major adverse clinical events in ST-segment elevation AMI patients undergoing primary PCI (P<0.0001).
Why the study?
Does baseline plasma myeloperoxidase (MPO) level predict 30-day MACE in patients with ST-segment elevation AMI undergoing primary PCI?
Observational (n=128)
Does baseline plasma myeloperoxidase (MPO) level predict 30-day MACE in patients with ST-segment elevation AMI undergoing primary PCI?
Answers are grounded in this paper and cite their sources.
High baseline plasma myeloperoxidase (MPO) level is a strong independent predictor of 30-day major adverse clinical events in patients with ST-segment elevation AMI undergoing primary PCI.
BACKGROUND: This study tested the hypothesis that the baseline plasma level of myeloperoxidase (MPO) independently predicts risk of patients with ST-segment elevation (ST-se) acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). METHODS AND RESULTS: Plasma MPO levels in 128 patients were examined by ELISA. They were significantly higher in AMI patients than in normal controls (P<0.0001). Patients with a high plasma MPO level (>or=1,150 ng/ml) had significantly higher white blood cell counts, a higher plasma level of oxidized low-density lipoprotein, higher peak MB fraction of creatine kinase level, significantly lower left ventricular ejection fraction, and significantly higher incidence of 30-day composite major adverse clinical events (MACE) (defined as Killip score>or=3, re-infarction, repeat PCI, or 30-day mortality) than those patients with low plasma MPO level (<1,150 ng/ml) (all P<0.001). Multiple stepwise logistic regression analysis demonstrated that high plasma MPO level (>or=1,150 pg/ml) was the most independent predictor of 30-day MACE (P<0.0001). CONCLUSIONS: Plasma MPO level is a major independent inflammatory predictor of 30-day MACE in ST-se AMI patients. Evaluation of the circulating MPO level might improve the prediction of unfavorable clinical outcome following AMI.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2009) conducted an observational in ST-segment elevation acute myocardial infarction (AMI) (n=128). High plasma myeloperoxidase (MPO) level (≥1,150 ng/ml) vs. Low plasma MPO level (<1,150 ng/ml) was evaluated on 30-day composite major adverse clinical events (MACE) (Killip score≥3, re-infarction, repeat PCI, or 30-day mortality) (p=<0.0001). High baseline plasma myeloperoxidase (≥1,150 ng/ml) was an independent predictor of 30-day major adverse clinical events in ST-segment elevation AMI patients undergoing primary PCI (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: